NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
Clinical Trials
34 trialsNCT06971744 2025-12-22
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Phase 2 Recruiting
NCT05843188 2025-12-09
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT00977470 2025-10-15
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05221320 2025-09-25
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT03037437 2025-09-04
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT04669197 2025-08-15
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting
NCT03377179 2025-07-23
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
RedHill Biopharma Limited
Phase 2 Completed
NCT04011410 2025-04-11
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
University of Kentucky
Phase 2 Completed
NCT04523857 2025-04-04
ABBY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04735068 2025-04-01
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT04841148 2025-03-11
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04386057 2025-02-12
LY3214996 +/- HCQ in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05518110 2024-09-26
PaTcH
Cancer Trials Ireland
Phase 2 Recruiting
NCT05689359 2024-03-08
Evaluation of Hydroxychloroquine to Prevent CIPN
University of Arizona
Phase 2 Withdrawn
NCT02316340 2024-01-05
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT04566133 2023-08-21
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00786682 2023-08-14
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT00726596 2022-06-16
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT04381988 2021-10-27
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01006369 2021-09-21
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT01494155 2021-02-02
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT04392128 2020-09-04
HYACINTHE
Institut de cancérologie Strasbourg Europe
Phase 2 Withdrawn
NCT03344172 2020-05-14
17-134
University of Pittsburgh
Phase 2 Terminated
NCT04341207 2020-04-10
ONCOVID
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT01978184 2019-03-27
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
University of Pittsburgh
Phase 2 Completed
NCT01602588 2018-05-03
HCQ
University College, London
Phase 2 Completed
NCT01273805 2017-06-14
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01828476 2017-05-04
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01842594 2015-11-03
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
Shin Kong Wu Ho-Su Memorial Hospital
Phase 2 Terminated
NCT01292408 2012-01-20
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients
Radboud University Medical Center
Phase 2 Unknown
NCT01227135 2011-11-30
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
University of Glasgow
Phase 2 Unknown